Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research note
  • Open Access

High prevalence of Pfmdr-1 N86 and D1246 genotypes detected among febrile malaria outpatients attending Lira Regional Referral Hospital, Northern Uganda

BMC Research Notes201912:235

https://doi.org/10.1186/s13104-019-4269-1

  • Received: 20 March 2019
  • Accepted: 15 April 2019
  • Published:

Abstract

Objective

To determine the prevalence of Plasmodium falciparum multi-drug resistant gene-1 (Pfmdr-1) N86Y and D1246Y genotypes among febrile malaria outpatients attending Lira Regional Referral Hospital, Uganda.

Results

Overall, 92.3% (n = 48/52) and 90% (n = 45/50) of the parasites detected carried the wild type alleles 1246D and N86, respectively. Only 7.7% (n = 4/52) and 10% (n = 5/50) of these P. falciparum isolates carried the Pfmdr-1 mutant alleles 1246Y and 86Y, respectively. Our results show high prevalence of wild type alleles N86 and D1246 in P. falciparum isolates from Lira Regional Referral Hospital, which could translate to a decreased sensitivity to artemether-lumefantrine. Continued monitoring of prevalence of single nucleotide polymorphisms is warranted to timely inform malaria treatment policies and guidelines.

Keywords

  • Malaria
  • Pfmdr-1
  • Mutation
  • Drug resistance
  • Genotypes
  • Prevalence
  • SNPs
  • Resistance

Introduction

Malaria mainly caused by an intracellular protozoan Plasmodium falciparum remains a serious infectious disease with high morbidity and mortality worldwide. In 2018, the sub-Saharan Africa accounted for 92% and 93% of the global malaria cases and deaths, respectively, with4% of the total world burden occurring in Uganda [1]. Uganda has a stable and perennial malaria transmission in 90–95% of the country, with a low and unstable transmission especially in the highlands usually with potential for epidemics [2].

In the absence of effective malaria vaccines, early and successful treatment is vital in reducing morbidity and mortality. However, the emergence and spread of antimalarial drug resistance has contributed to a global increase in malaria related deaths [3]. Previously, resistance to chloroquine (CQ) and sulfadoxine–pyrimethamine (SP) hampered malaria control efforts resulting in the adoption of artemisinin-based combination therapy (ACT) as the standard treatment for uncomplicated P. falciparum malaria [4, 5]. ACT consists of a rapid-acting artemisinin derivative with a longer-acting partner drug that clears parasites not eliminated by the artemisinin component and limits selection of artemisinin resistance [6, 7]. The re-infecting parasites are exposed to slowly declining drug concentrations during clearance of the long-acting partner drug and a shorter post-treatment prophylactic effect could reduce the ACT to an artemisinin derivative monotherapy [8]. In 2004, artemether-lumefantrine (AL) was adopted as the first line treatment for uncomplicated malaria in Uganda, with artesunate/amodiaquine (AS/AQ) as its alternative [9].

Mutations in P. falciparum genes, identified as single nucleotide polymorphisms (SNPs) are markers of anti-malaria drug resistance which allow for the monitoring of declining drug susceptibility in parasite populations [1012]. For partner drugs in the national treatment regimens AL and AS/AQ, increased risk of treatment failure and decreased susceptibility to lumefantrine in vitro are associated with N86, 184F, D1246, K76 alleles of Pfmdr-1 [11, 13, 14]. AQ resistance is associated with Pfmdr-1 alleles 86Y, Y184 and 1246Y; P. falciparum chloroquine resistance gene (Pfcrt) alleles 76T and SVMNT while CQ resistance is associated with 86Y and 76T alleles of Pfmdr-1 and Pfcrt genes respectively [13, 15]. Over the years, changes in malaria treatment practices have resulted in changes in the above markers of resistance. This study aimed at assessing the prevalence of Pfmdr-1 N86Y and D1246Y polymorphisms in P. falciparum isolates collected from malaria outpatients at Lira Regional Referral Hospital (LRRH), Uganda. We observed a high prevalence of wild type alleles N86 and D1246 and low prevalence of the mutant type alleles 86Y and 1246Y, which could translate to a decreased AL sensitivity in the region.

Main text

Methods

Study sites and population

This study was conducted in Lira regional referral hospital (LRRH), Lira district, Northern Uganda (1°21′N 02°42″N and 32°51″E 34°15″E), a high-endemic malaria area, located approximately 340 km north of Kampala, covering an area of approximately 1326 km2. Malaria is present throughout the year, with seasonal peaks of transmission coinciding with the rains (March–May and September–December). LRRH is the only regional referral facility in the sub-region, offering both specialized clinical cares, including HIV/AIDS and general clinical services. The study population consisted of febrile malaria clients attending the antiretroviral therapy (ART, 251 patients) and out patients' department (OPD, 520) clinics. Patients diagnosed with P. falciparum malaria between April and July 2015 based on Giemsa-stained thick and thin blood films were included in the study after obtaining informed consent. Inclusion criteria were individuals who presented with fevers and had taken anti-malarial drug ACT at least once during the 12 months prior to the study.

Sample collection

Fingerpick samples of blood spots were collected on chromatography filter paper (Lasec, Munktell TFN), air-dried, labeled and stored at − 80 °C in plastic envelopes containing silica gel until further processing. Plasmodium falciparum microscopically positive samples were used for this study and all patients diagnosed to have malaria infections were treated with artemether-lumefantrine (Coartem).

DNA extraction, PCR and RFLP assays

Plasmodium falciparum DNA was extracted from all filter paper dried blood samples using TRIzol reagent LS (Epigenetics USA) as per manufacturer’s protocol. Outer and nested PCR were performed for codons 86 and 1246 of Pfmdr-1 on all microscopically positive samples following the protocol developed by Humphreys et al. [16], followed by restriction length polymorphism (RFLP) digestion using restriction enzymes as previously described by Thomsen et al. [17].

Statistical analysis

Data was analyzed using descriptive statistics in STATA version 12 (StataCorp, College Station, TX, USA). The count of samples with mutant and wild type alleles were used to generate prevalence of the Pfmdr-1 N86Y and D1246Y alleles.

Results

Prevalence of the SNPs in the pfmdr-1 gene

Out of the 200 microscopically positive samples screened for Pfmdr-1 SNPs polymorphism (22 from ART and 178 from OPD clinics), 29.5% (n = 59/200) and 27.5% (n = 55/200) contained the outer codons c86/c184 and c1246, respectively. 84.7% (n = 50/59) and 94.5% (n = 52/55) of these samples were genotyped at codons 86 and 1246 with the elimination samples which did not amplify in the nested PCR. Our results indicate a 90% (n = 45/50) prevalence of the wild type 86N allele compared to 10% (n = 5/50) of the mutant 86Y allele (Table 1). Similarly, we observed a 92.3% (n = 48/52) prevalence of wild 1246 alleles compared to 7.7% (n = 4/52) of the mutant alleles in the study population (Table 1).
Table 1

Prevalence of Pfmdr-1 polymorphisms among isolates from P. falciparum patients from LRRH, Uganda

SNPs codon

Pfmdr-1 alleles

Examined

Positive

Prevalence %

Codon 1246

Wild (1246D)

52

48

92.3

Mutant (1246Y)

52

4

7.7

Codon 86

Wild (N86)

50

45

90.0

Mutant (86Y)

50

5

10.0

SNPs: single nucleotide polymorphism, Pfmdr-1: P. falciparum multidrug resistance 1 gene

Discussion

We examined the prevalence of Pfmdr-1 N86Y and D1246Y genotypes associated with altered drug sensitivity in febrile outpatients at LRRH utilising AL, the national treatment regimen. The prevalence of the wild type N86 and D1246 alleles were high in comparison to the mutant 86Y and 1246Y alleles (Table 1). The widespread use of AL to treat malaria has increased both the prevalence and frequency of Pfmdr-1 wild alleles N86 and D1246, with a decrease in the sensitivity to lumefantrine and increased sensitivity to aminoquinolines [18]. Our results correlate with the findings of increased prevalence of wild type N86 and D1246 polymorphisms associated with treatment failures and decreased sensitivity to lumefantrine in Tororo, Uganda [19, 20]. Like in our study, a previous study by Okombo [21] in the neighbouring Kenya also observed a significant increase in the prevalence of wild type pfmdr1 N86/Y184/D1246 haplotype and a corresponding decline of the mutant pfmdr1 86Y/184Y/1246Y after 19 years (1995–2013) of chloroquine removal. This finding and ours highlight the importance of continued monitoring and characterization of parasite genotypes as a way to audit the therapeutic efficacy of drugs in clinical use and those previously withdrawn. The recurrent malaria infections prior to treatment with AL are associated with decreased lumefantrine sensitivity, and increased N86 genotypes could suggest significant risk factors for recrudescence in patients treated with AL [11, 18]. Interestingly, AL and AS/AQ exert opposing selective effects on the SNPs in Pfcrt and Pfmdr-1 genes [11].

By year 2000, the CQ resistance in one of the eastern districts in Uganda, were over 90% [20]. In this study we found low prevalence of the mutant 86Y and 1246Y alleles which corroborates with previous findings of a gradual decrease in mutant 86Y and 1246Y genotypes in Uganda in between 2003 and 2012, following the withdrawal of CQ [20]. Prior to the withdrawal of CQ in Uganda, the CQ parasitological resistance levels ranged from < 5 to > 50% [22]. The low mutant of 86Y and 1246Y genotypes could have resulted from the decreased use of CQ and widespread use of AL as the standard anti-malarial drug in LRRH. A decreasing CQ exposure, and increased lumefantrine exposure selects for wild type sequences at these alleles [16, 23, 24]. Additionally, the low scale use of the AS/AQ, alternative first line drug for treatment of uncomplicated malaria could partly explain the low prevalence of the mutant alleles. Taken together, the current study suggests a prevalence rate of wild type alleles 1246D and N86 of about 90% compared with other studies in the region, which by 2012 was about 50% [20], suggesting high risk of treatment failures by AL. However, thus far, treatment of severe malaria in children below 20kg with intravenous AL was effective [25] indicating that, drug resistance to AL have not spread in the area.

In conclusion, our results demonstrated a high prevalence of wild type alleles N86 and D1246 that are likely to mediate decreased sensitivity to artemether-lumefantrine in the Lira RRH outpatients’ clinics. However, the mutant 86Y and 1246Y alleles showed a low prevalence owing to the decreased use of CQ and low use of AS/AQ, the alternative first line regimen in Uganda. A sustained success in malaria control is strongly dependent on the continued effectiveness of treatment using ACT, thus the need for continued countrywide monitoring of the Pfmdr-1 SNPs.

Limitations

We acknowledge limitations in the study including;
  • The small sampling size involving only 771 out patients at LRRH participating in this study and small number of the resistance mediating polymorphism was considered.

  • The possibility of sampling bias as a P. falciparum specific rapid kit was used for screening and existence of HRP2 and HRP3 mutant parasites.

  • Low parasitemia could have led to potential false negative results especially in semi immune populations in the study area.

  • The Afl-III enzyme used in genotyping could not recognize and digest both 86Y and 86F, and thereby unable to differentiate between them. However, the 86F genotype has only been reported in one study from Swaziland and not in Uganda or East Africa [26] thus all digestions with Afl-III were considered 86Y isolates.

Abbreviations

ACT: 

artemisinin combination therapy

AL: 

artemether-lumefantrine

ART: 

anti-retroviral therapy

AQ: 

amodiaquine

DNA: 

deoxyribonucleic acid

IRB: 

Institutional review board

LRRH: 

Lira Regional Referral Hospital

PCR: 

polymerase chain reaction

Pfcrt

Plasmodium falciparum chloroquine resistant gene

Pfmdr-1

Plasmodium falciparum multi drug resistant gene-1

RFLP: 

restricted fragment length polymorphism

SNPs: 

single nucleotide polymorphisms

Declarations

Authors’ contributions

EA, SO, HE, GMM and RE conceived the study. EA collected data, performed experiments together with HE and later drafted the manuscript. All authors participated in analysis of the results. All authors read and approved the final manuscript.

Acknowledgements

We thank the study clients, management and staff of Lira RRH for the support rendered during the sample and data collection phase of this study.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The authors declare that all the main data supporting the findings of this study are available within the article. Any additional data sets are available from the corresponding author upon reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board (IRB) of St Mary’s Hospital Lacor, (No. LHIREC: 069/11/14). Permission to conduct this study was later granted by the management of Lira regional referral hospital and written informed consent and assent were obtained from the adult participants and caregivers, respectively.

Funding

This work was a students’ funded project.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biology, Faculty of Science, Gulu University, P.O. Box 166, Gulu, Uganda
(2)
Department of Immunology and Microbiology, Gulu University, P.O. Box 166, Gulu, Uganda
(3)
Gulu University Bioscience Research Laboratories, P.O. Box 166, Gulu, Uganda
(4)
Department of Environmental and Biological Sciences, University of Eastern Finland, P.O. Box 111, 80101 Joensuu, Finland

References

  1. WHO. World malaria report. 2018. ISBN 978 92 4 156469 4. 2018. http://www.who.int/malaria. Accessed 22 Nov 2018.
  2. USAID UPMI. President’ S Malaria Initiative Angola. USAID. 2018;1–111.Google Scholar
  3. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in Western-Kenya P. falciparum samples during 2008–2011. PLoS ONE. 2013;8(5):e64299.View ArticleGoogle Scholar
  4. Nanyunja M, Nabyonga Orem J, Kato F, Kaggwa M, Katureebe C, Saweka J. Malaria treatment policy change and implementation: the case of Uganda. Malar Res Treat. 2011;2011:1–14.View ArticleGoogle Scholar
  5. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89(6):1025–38.View ArticleGoogle Scholar
  6. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2018;77(6_Suppl):181–92.View ArticleGoogle Scholar
  7. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7(12):864–74. https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=2009600571
  8. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether–lumefantrine tolerance/resistance in Bagamoyo district Tanzania. Malar J. 2013;12(1):1–7.View ArticleGoogle Scholar
  9. Ministry of Health (Uganda). The Uganda malaria reduction strategic plan 2014–2020. 2014:1–83.Google Scholar
  10. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the Western Border of Thailand. Antimicrob Agents Chemother. 2018;43(12):2943–9.View ArticleGoogle Scholar
  11. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether–lumefantrine and artesunate–amodiaquine. Am J Trop Med Hyg. 2014;91(4):833–43.View ArticleGoogle Scholar
  12. Djimdé A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet. 2001;358(9285):890–1.View ArticleGoogle Scholar
  13. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether–lumefantrine in Africa. J Infect Dis. 2009;199(5):750–7.View ArticleGoogle Scholar
  14. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009;53(12):5069–73.View ArticleGoogle Scholar
  15. Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Björkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT Partner Drug Molecular Surveyor. Malar J. 2019;18(1):1–10. https://doi.org/10.1186/s12936-019-2645-x View ArticleGoogle Scholar
  16. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and artemether–lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian Children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2006;51(3):991–7.View ArticleGoogle Scholar
  17. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, et al. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Am J Trop Med Hyg. 2011;85(6):979–83.View ArticleGoogle Scholar
  18. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites Isolated from Ugandan children. Antimicrob Agents Chemother. 2015;59(6):3018–30.View ArticleGoogle Scholar
  19. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and Falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;9(8):e105690.View ArticleGoogle Scholar
  20. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg. 2014;91(1):54–61.View ArticleGoogle Scholar
  21. Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-Oyier LI. Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4(3):152–63. https://dx.doi.org/10.1016/j.ijpddr.2014.07.003
  22. Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health. 2002;7(12):1031–41. https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=2003323419
  23. Lobo E, De Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J. 2014;13(1):1–6.View ArticleGoogle Scholar
  24. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether–lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006;50(5):1893–5.View ArticleGoogle Scholar
  25. Byakika-Kibwika P, Nyakato P, Lamorde M, Kiragga AN. Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial. Malar J. 2018;17(1):400. https://doi.org/10.1186/s12936-018-2552-6.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Dlamini SV, Beshir K, Sutherland CJ. Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malar J. 2010;9(68):1–9. https://www.malariajournal.com/content/9/1/68

Copyright

© The Author(s) 2019

Advertisement